The latest price target for Biohaven (NYSE:BHVN) was reported by HC Wainwright & Co. on May 26, 2026. The analyst firm set a price target for $10.00 expecting BHVN to fall to within 12 months (a possible -12.05% downside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Biohaven (NYSE:BHVN) was provided by HC Wainwright & Co., and Biohaven reiterated their neutral rating.

The last upgrade for Biohaven Ltd happened on January 21, 2026 when RBC Capital raised their price target to $22. RBC Capital previously had a sector perform for Biohaven Ltd.

The last downgrade for Biohaven Ltd happened on December 3, 2025 when HC Wainwright & Co. changed their price target from $30 to $11 for Biohaven Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biohaven, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biohaven was filed on May 26, 2026 so you should expect the next rating to be made available sometime around May 26, 2027.

While ratings are subjective and will change, the latest Biohaven (BHVN) rating was a reiterated with a price target of $10.00 to $10.00. The current price Biohaven (BHVN) is trading at is $11.37, which is out of the analyst’s predicted range.